Invited Commentary
Copyright ©The Author(s) 2001. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 15, 2001; 7(6): 777-778
Published online Dec 15, 2001. doi: 10.3748/wjg.v7.i6.777
Moving toward an understanding of the metastatic process in hepatocellular carcinoma
W Michael Korn
W Michael Korn, Division of Gastroenterology and Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143-0128, USA
Author contributions: The author solely contributed to the work.
Correspondence to: UCSF Comprehensive Cancer Center, 2340 Sutter St. San Francisco, CA 94115, USA.
Telephone: +1-415-502-2844, Fax: +1-415-502-3179
Received: October 12, 2001
Revised: October 29, 2001
Accepted: November 3, 2001
Published online: December 15, 2001

Key Words: carcinoma, hepatocellular/pathology, clone cells, tumor cells, cultured, neoplasms metastasis

Citation: Korn WM. Moving toward an understanding of the metastatic process in hepatocellular carcinoma. World J Gastroenterol 2001; 7(6): 777-778

Clinical factors contributing to the therapeutic challenge of hepatocellular carcinoma (HCC) are manifold: tumors arise often in patients with compromised liver function, therefore limiting therapeutic options; symptoms develop only at later stages of tumor progression, and tumors tend to invade normal structures or occur in multiple locations simultaneously. Ninety percent of patients with tumors larger than 5 cm will have synchronous intrahepatic metastases at the time of presentation. In the majority of patients undergoing partial hepatectomy for HCC, intra-hepatic or distant metastases will occur[1]. Likewise, in about fifty percent of the patients who die within five years after liver transplantation for HCC, intra- and extrahepatic recurrences are the cause of death[2]. Tumor characteristics predicting recurrence of HCC following resection include portalvein invasion, intrahepatic metastasis, extratumoral spread, high mitotic index [3-5], and a sarcomatous phenotype[6]. Such observations demonstrate that tumor cells that are easily invading normal tissues and achieve access to the circulation harbor the greatest risk of tumor recurrence. The molecular events promoting invasiveness of HCC cells are still widely unknown. Further understanding of these processes is urgently needed for the development of rational strategies for prevention and treatment of metastatic disease in HCC.

Investigations in different tumor types and murine models of cancer depict a characteristic cascade of events necessary for a tumor to achieve successful dissemination of metastases from a primary tumor. After malignant transformation and initial tumor growth, the first step towards metastasis formation is the initiation of vascularization of the tumor, a process known as the angiogenic switch. While the tumor progresses, new genetic changes occur leading to ① a reduced cell-cell adhesion, and, ② alterations in the interaction of the tumor cell with the extracellular matrix, allowing invasion into surrounding tissues including blood vessels (which are mediated by changes in integrin expression and activation of proteolytic enzymes). Tumor cells reaching the circulation must have developed mechanisms to suppress anoikis, which is programmed cell death caused by disruption of cell-substrate adhesion. At distant sites, tumor cells need to leave the circulation and migrate to sites with favorable conditions. Here, angiogenesis is again initiated and cell progression of the metastasis continues. It is obvious that this sequence of events will be dependent on multiple molecular factors in malignant and normal (e.g. stroma and immune competent) cells. Some of these factors have been characterized in HCC. So far, and in agreement with data from other tumor types, there is evidence that a high proliferative index (as measured by PCNA or Ki-67 expression) is associated with reduced tumor differentiation and might be predictive of recurrence after tumor resection[7-9]. In HCC, several signalingpathways are candidates for driving this proliferation, mainly those related to growth factor receptors, including Met, the receptor for the hepatocyte growth factor/scatter facter (HGF/SF) and epidermal growth factor receptor (EGFR)[10,11]. While enhanced proliferation is an important step during tumorigenesis, increases in invasiveness and cell mobility are necessary for the generation of metastases. It has been demonstrated that signaling through the Ras/MAPK pathway (which confers signals from growth factor receptors, including EGFR and Met), could cooperate with the TGF-β signal transduction pathway in promoting the switch from a epithelial to mesenchymal phenotype in cancer cells, rendering them significantly more mobile and invasive[12]. In vitro data from HCC cell lines support this possibility, as it has been demonstrated that TGF-β signaling enhances proliferation of HCC cell lines[13]. Disassembly of protein complexes involved in cell-cell adhesion has been demonstrated as a consequence of TGF-β and Ras/MAPK signaling[14]. Accordingly, loss of expression of the cell-adhesion molecule E-cadherin and nuclear expression of its binding partner β-catenin, occurs frequently in high-grade HCC and correlates with a poor prognosis[15]. There is also strong evidence that HCC indeed activates angiogenesis. For example, vascular endothelial growth factor (VEGF), a promoter of angiogenesis, was found to be upregulated in HCC[16]. A recent prospective study in 100 patients undergoing resection of HCC demonstrated a strong correlation between serum concentration of vascular endothelial growth factor (VEGF) and microscopic vascular invasion[17]. In the same study, high serum levels were associated also with the presence of intrahepatic metastases and reduced disease-free survival. As indicated, successful invasion into surrounding tissues can also be facilitated by proteases that allow malignant cells to migrate through physiologic barriers, e.g. basement membranes. Indeed, experiments using HCC cell lines revealed that membrane-type 1 matrix metal loproteinase confer invasiveness and promote intrahepatic metastases[18]. In addition, expression of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR) and plasminogen activator inhibitor type-1 (PAI-1) was found to be associated with tumor invasiveness in a mouse model of HCC and human HCC[19]. Overall, these data suggest that mechanisms of metastasis in HCC that are consistent with data in other types of solid tumors. However, most of the evidence is circumstantial and correlative, reflecting a lack of appropriate model systems.

As Li et al describe in this issue of the World Journal of Gastroenterology, new model systems might be available that could lend insight into the mechanisms underlying the metastatic process in HCC. The authors generated two clonally related cell line derivatives from human HCC cell line MHCC97 that show dramatic differences in their metastatic potential. Notably, the authors used an in vivo selection process that included the orthotopic transplantation of xenografts into the livers of mice, thus simulating the clinical situation as closely as possible. The differences in metastatic potential were mirrored by significant phenotypical differences. These included morphologic differences as well as faster proliferation, enhanced in vitro invasiveness, and increased alpha-fetoprotein (AFP) production of the highly malignant derivative compared to its less metastatic counterpart. These findings are consistent with the expected metastatic phenotype of H CC and it will be most exciting to see results from molecular analyses of these cells. Particularly, analyses of differential gene expression, e.g. using cDNA expression arrays, will be revealing and could be compared to results from the analysis expression profiles in human tumors[20].

Identification of differentially expressed genes represents an important step toward understanding metastasis in this disease. However, genetic evidence will be necessary to pinpoint the culprits in this process. So far, transgenic mouse models of HCC have been created in which liver-specific expression of potential oncogenes, including Cyclin D1, c-myc, TGF-a, and Met leads consistently to the development of HCC-like tumors[21,11,22]. Interestingly, tumors occurring in these models lack a highly invasive or metastatic phenotype. A next step is to rebuild the full phenotype of HCC in mice using modified transgenic models that include combinations of growth and metastasis promoting genes. Based on these models, rational therapeutic approaches could be developed and tested.


Edited by Pan BR

See article on Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. P World J Gastroenterol, 2001; 7(5):630-636

1.  Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer. 2001;91:2378-2385.  [PubMed]  [DOI]
2.  Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.  [PubMed]  [DOI]
3.  Ouchi K, Sugawara T, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J, Yamanami H, Nakagawa K. Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection. J Surg Oncol. 2000;75:241-245.  [PubMed]  [DOI]
4.  Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-507.  [PubMed]  [DOI]
5.  Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome. Cancer. 2000;88:538-543.  [PubMed]  [DOI]
6.  Yamanaka J, Yamanaka N, Nakasho K, Tanaka T, Ando T, Yasui C, Kuroda N, Takata M, Maeda S, Matsushita K. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection. J Gastroenterol Hepatol. 2000;15:1192-1198.  [PubMed]  [DOI]
7.  Hino N, Higashi T, Nouso K, Nakatsukasa H, Urabe Y, Kinugasa N, Yoshida K, Ashida K, Ohguchi S, Tsuji T. Proliferating cell nuclear antigen and grade of malignancy in small hepatocellular carcinoma--evaluation in US-guided specimens. Hepatogastroenterology. 1997;44:245-250.  [PubMed]  [DOI]
8.  Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167-1175.  [PubMed]  [DOI]
9.  Suehiro T, Matsumata T, Itasaka H, Yamamoto K, Kawahara N, Sugimachi K. Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen. Cancer. 1995;76:399-405.  [PubMed]  [DOI]
10.  Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999;19:318-325.  [PubMed]  [DOI]
11.  Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol. 2001;153:1023-1034.  [PubMed]  [DOI]
12.  Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10:2462-2477.  [PubMed]  [DOI]
13.  Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, Yamashiki N, Seki T, Saito H, Nishizawa M. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 2000;60:1394-1402.  [PubMed]  [DOI]
14.  Chen Yh, Lu Q, Schneeberger EE, Goodenough DA. Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol Biol Cell. 2000;11:849-862.  [PubMed]  [DOI]
15.  Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol. 2000;31:558-565.  [PubMed]  [DOI]
16.  Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997;27:854-861.  [PubMed]  [DOI]
17.  Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001;233:227-235.  [PubMed]  [DOI]
18.  Murakami K, Sakukawa R, Ikeda T, Matsuura T, Hasumura S, Nagamori S, Yamada Y, Saiki I. Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase. Neoplasia. 1999;1:424-430.  [PubMed]  [DOI]
19.  Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol. 2000;126:641-646.  [PubMed]  [DOI]
20.  Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61:2129-2137.  [PubMed]  [DOI]
21.  Santoni-Rugiu E, Jensen MR, Thorgeirsson SS. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res. 1998;58:123-134.  [PubMed]  [DOI]
22.  Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 2001;61:5389-5395.  [PubMed]  [DOI]